Solvay expands its specialty polymers offerings with Ryton PPS acquisition

Similar documents
Building a new model of sustainable chemistry. Meeting with Investors at VFB-Happening 2014 Karim Hajjar CFO

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

Table of Contents. 1. About Solvay Solvay at a Glance Group Portfolio Transforming Solvay Solvay s Portfolio Upgrade 7

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

BALCHEM CORPORATION. Q Investor Relations Presentation

January 30, 2018 Dow Wilson President and Chief Executive Officer

CPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018

An exciting combination in a high growth, high margin Nutrition category. Name of chairman

DSM Capital Markets Day 2018

The acquisition of Fortitech

Global Polybutylene Terephthalate (PBT) Market Study ( )

Global Terephthalic Acid (PTA) Market Study ( )

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Solvay India April 2017

William Demant. Jefferies Healthcare Conf. Nov Søren B. Andersson, VP Investor Relations

Nutrition Chris Goppelsroeder President & CEO DSM Nutritional Products ROYAL DSM HEALTH NUTRITION MATERIALS

Dentivera Milling Discs. Powering the Digital Revolution. Supported by Solvay. Make METAL-FREE Possible with Ultaire AKP. Dental Lab Advantages

Driving Profitable Growth

Coloplast A/S. Investor presentation 1H 2005/06

Global EHS Leaders Survey 2017: EHS Consulting Brands

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

Harm de Wildt MD TNI

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

Forward Looking Information

To be the partner of choice Straumann

Launch of a new binders : Leveraging innovation to an economic advantage.

Global Zinc Chemicals Market Study ( )

Vision. Mission. Hopelink s Values. Introduction. A community free of poverty

1Q2005. Hera Group presentation

Opening New Frontiers

GROWTH NOW! Franck Riboud

The Dental Corporation Opportunity

Letter to Shareholders SEMI-ANNUAL REPORT 2008

Myriad Genetics Corporate Presentation 06/13/2018

Solvay in India January, 2014

Ipsen Oddo BHF Forum January 12, 2018

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free

ManagementStudyGuide.com. Visit

Food & Beverages Food for a growing world

Food Specialties Patrick Niels President DSM Food Specialties ROYAL DSM HEALTH NUTRITION MATERIALS

Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO

A GLOBAL LEADER IN PERSONALIZED NUTRITION

Delivering Results POSITIONED FOR GROWTH. Analyst & Investor Day October 14, 2015 Paul Guggenheim CEO, Patterson Dental

Human Nutrition Jeremy Xu President Human Nutritional & Health ROYAL DSM HEALTH NUTRITION MATERIALS

Continuing the momentum to deliver improved performance. Robert Cascella Chief Business Leader Diagnosis & Treatment

Chronic Care. Coloplast Capital Market Day Jan Rolin Frederiksen, President Coloplast US. Coloplast Capital Market Day 2009

Blood Flow Measurement Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, Single User License: US $ 4595

Coloplast A/S. Investor Presentation 2005/06

ASX Announcement 22 June 2017

Financial Presentation

Südzucker Group Capital market forum Rhine Neckar

Consumer Wellness in India Growth Ahead

Cochlear Limited 2017 Annual General Meeting Chairman s Address

For personal use only

JP Morgan 2011 Healthcare Conference. David Redfern, Chief Strategy Officer 12 January 2011

Chronic Care North America update Coloplast Capital Markets Day 2018 Manu Varma, Senior Vice President, Chronic Care Management, NA

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region

Value growth in Human Nutrition & Health

Jefferies Healthcare Conference

Boston Scientific is advancing...

BUILDING BUSINESS THROUGH SYNERGY

ADM to Acquire WILD Flavors

Page 2 Meet Management in Tokyo November Bayer in Asia/Pacific

Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO

Partnering for Growth

The value of integrated reporting

Nomura Healthcare Conference

Wednesday 26 th November 2008 The ASX Company Announcements office: Chairman s AGM Address

Full Year Update FY2011 May 2011

KAPITALMARKNADSDAG 20 SEPTEMBER Thomas Axelsson, CEO

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Building a model of sustainable chemistry

Health for Humanity 2020 Goals 2

2015 Investor Conference

AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes

AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

Efforts start to pay off in the fourth quarter

Leading Intimate Healthcare. Investor presentation Q1 2007/08

A world leader in allergy immunotherapy

Nordea investor meeting. June 18 th, 2018 Kristian Villumsen, EVP Chronic Care

Going Digital. Investora Gerhard Mahrle CFO COLTENE Holding AG. September 21, 2017

Very good Q3 contribution from Vegetable Juices Inc.

Welcome to the Full -Year Results Press Conference

Global Hearing Aid Battery Market: Analysis By Battery Type, By Region, By Country: Trends, Opportunities, Restraints (2018 Edition) Forecast to 2022

Bank of America Merrill Lynch HealthCare Conference Bayer HealthCare Dr. Jörg Reinhardt. September 14, 2011

Chronic Care Coloplast Meet the Management London 2017 Kristian Villumsen, EVP Chronic Care Edmond Veome, SVP Chronic Care North America

Ipsen Acquisition of Clementia Pharmaceuticals. February 25, 2019

ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT

Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria

Country Coverage. Company Coverage

Chronic illness is a growing market for Novo Nordisk

Strategic Business Overview. Bernard HOURS

Closing of Nucletron acquisition Building a stronger position in the cancer care market. September 15, 2011

Contour Your Body Quickly and Comfortably!

STRATEGIC PLAN

Partnering in Oncology Sharing a Vision to Help Prolong and Improve Patients Lives. Oncology Therapeutic Area Janssen Research & Development, LLC

Imaging Systems. Gene Saragnese EVP and GM Imaging Systems

Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America

Transcription:

Solvay expands its specialty polymers offerings with Ryton PPS acquisition

Sustained strategic portfolio realignment With Ryton PPS* acquisition, Solvay further strengthens unmatched leadership in Specialty Polymers solutions Additional step in Solvay s in-depth transformation towards a higher growth, less cyclical and greater returns Group * PPS: PolyPhenylene Sulfide 2

Compelling strategic rationale Ryton PPS*, a strong business fit Further enhance Specialty Polymers unmatched broad solutions portfolio Attractive market with solid growth (CAGR 7%) driven by climate change, related regulations and population growth Significant synergies Cross-selling (products and customers) opportunities Cost synergies: joint R&D, manufacturing excellence, purchasing, marketing and sales, and logistics Solvay crucial engineering and operational excellence know-how to rampup the new plant based on a highly innovative PPS technology * PPS: PolyPhenylene Sulfide 3

Ryton PPS in a nutshell Key figures Product North America Asia & RoW 22% 32% Net sales 2013 46% Industrial Footprint United States Europe Net sales 2013 ~ 100 m Workforce ~ 200 employees Belgium Kallo-Beveren compounding 1st PPS brand created 40 years ago PPS meeting highest performance standards Strong brand recognition among Auto OEM/OES "In Auto, Ryton is like Kleenex for tissues" "Automotive tends to speak Ryton " Borger resin Bartlesville pilot plant La Porte (compounding) Not taken over, but temporary tolling agreement Singapore Singapore application lab (assets) Competitor/ Distributor 4

Ryton PPS offers strong business fit & synergies Business fit Complements and extends materials portfolio Increases exposure to strategic markets of advanced transportation and clean technologies Increases potential in strategic emerging markets like thermoplastic composites Synergies Benefits from Specialty Polymers core manufacturing and innovation competencies Leverages Specialty Polymers market leadership Leverages Specialty Polymers business strength 5

PA 6.6 Thermal stability ( C) Ryton PPS extends product portfolio functionalities to Solvay s customers 260 240 220 Ryton PPS LCP PEEK 280 C 200 180 PEI 160 PSU 140 PPA 120 PPS is the optimal material for specific market segments that Specialty Polymers wants to penetrate 100 Cost ($/cm³) PPS provides a unique combination of price, mechanical strength, chemical resistance and thermal stability that complements our existing polymers portfolio 6

Solvay s unique solution offering to its customers further strengthened by Ryton PPS Aromatics Fluoropolymers High-barrier polymers X-linkable compounds LCP HPPA PPS PEEK PAI PSU PTFE PVDF PFA FKM PFPE PVDC XLCP Automotive Advanced Transportation Oil & Gas Renewable Energy Healthcare Smart Devices Water Other markets 7

Solvay s unique solution offering to its customers further differentiates it from its competitors Aromatics Fluoropolymers High-barrier polymers X-linkable compounds LCP HPPA PPS PEEK PAI PSU PTFE PVDF PFA FKM PFPE PVDC XLCP Ryton 8

Ryton PPS enhances Solvay s growth potential Solvay Specialty Polymers Net Sales 2013 1.3 bn Global PPS applications Market size (in volume) 64 kt CAGRe 2013-2020 +7% Strong growth in Automotive 0,5 kg /vehicle Advanced transportation Consumer Healthcare Water Energy Construction 12% 2% 11% 3% 8% 10% 22% 16% 10% 8% Automotive E&E Smart devices Industrial Other 30% 27% 27% 16% +7% +7% +5% +8% Motor insulators 2.5 kg /vehicle ECU / Control unit IPM / Power module New PPS applications in Automotive are emerging from Hybrid and Electric Vehicles 9

Ryton PPS easily integrated in Solvay Specialty Polymers regional set-up Ryton PPS sites NORTH AMERICA 8 production sites (1 Ryton PPS) 3 R&I centers (1 Ryton PPS) EUROPE 7 production sites (1 Ryton PPS) 1 R&I centers Resin production plant Borger (TX, USA) Compounding plant Kallo-Beveren (Belgium) ASIA & RoW 2 production sites 5 R&I centers (1 Ryton PPS) Pilot line Bartlesville (OK, USA) Application lab (assets) Singapore Solvay Specialty Polymers sites Production plants R&I centers 2% 27% Net sales 2013 31% 40% Specialty Polymers + Ryton PPS pro forma 10

Transaction terms & financial considerations Cash transaction US$ 220 M (~ 170 m) Taken over from Important synergies, compelling returns Solvay will invest and use its engineering and operational excellence know-how to ramp-up the highly innovative new PPS plant 2016, start of meaningful REBITDA contribution after transition integration year CFROI > WACC as from 2018 Closing expected by YE 2014 Transaction subject to customary closing conditions, including anti-trust clearance in US 11

Ryton PPS acquisition, further underpinning Specialty Polymers key contribution to Solvay s growth ambition Market leader, serving best solutions to customers REBITDA Ryton PPS further enhancing broadest solution offering and expanding addressable market Supplying highly dynamic growth markets driven by ever increasing demand for sustainable solutions CAGR +12% 2-digit CAGR Delivering value through innovation, market growth and operational excellence 2010 2013 2016e Ryton PPS 1 st REBITDA contribution 12

Take-aways Ryton PPS acquisition further improves Solvay s business profile Further strengthening Specialty Polymers growth engine leading position Strong growth prospects Significant synergies CFROI > WACC as from 2018 Pursuing Solvay s transformation 13

Forthcoming 2014 key events 13 November 2014 Q 3 r e s u l t s p u b l i c a t i o n 14

www.solvay.com